Alnylam RNAi Therapeutics

Alnylam Pharmaceuticals is a pioneer in the field of RNA interference (RNAi) therapeutics, a class of medicines designed to silence specific genes involved in the cause or pathway of various diseases. Founded in 2002 by a group of distinguished scientists, including Nobel laureate Phillip Sharp, the company was established to translate the discovery of RNAi into a whole new class of innovative medicines. Their portfolio includes several marketed drugs such as ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, targeting rare genetic, cardiometabolic, and infectious diseases.

While the brand originated in Cambridge, Massachusetts, its manufacturing footprint is global. Alnylam operates a significant internal manufacturing facility in Norton, Massachusetts, which produces the drug substances for its clinical and commercial programs. To ensure a resilient supply chain and meet global demand, the company also utilizes a network of specialized Contract Manufacturing Organizations (CMOs) across North America, Europe, and Asia. This hybrid model allows the brand to maintain high-quality standards while scaling production for international markets.

Alnylam remains a publicly traded, independent entity currently headquartered in the United States. Its ownership is primarily held by institutional investors, though it maintains strategic collaborations and licensing agreements with global giants like Roche, Sanofi, Novartis, and Regeneron. These partnerships are instrumental in the distribution and co-development of specific therapies within Alnylam's extensive pipeline, ensuring that their breakthrough RNA-based treatments reach patients worldwide.